Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.30 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25458468 | 0.85 | DCTPP1 (0.31) | NPC1DCTPP1TDP1RECQLRAB9A | |
| SCHEMBL25175972 | 0.82 | ALDH1A1 (0.33) | NPC1F2RL1DGAT1TDP1RECQL | |
| SCHEMBL25170244 | 0.80 | ALOX5AP (0.35) | NPC1F2RL1DGAT1 | |
| SCHEMBL14910262 | 0.79 | KDR (0.37) | NPC1DCTPP1TDP1RECQLRAB9A | |
| SCHEMBL4718604 | 0.78 | TDP1 (0.37) | NPC1DCTPP1TDP1RECQLRAB9A | |
| SCHEMBL10076076 | 0.76 | TDP1 (0.36) | DCTPP1TDP1HSD17B10ALDH1A1 | |
| SCHEMBL14910863 | 0.75 | TDP1 (0.39) | NPC1TDP1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL31411406 | 0.75 | F2RL1 (0.32) | NPC1F2RL1DGAT1RAB9AALDH1A1 | |
| SCHEMBL6286068 | 0.74 | KDM4E (0.39) | NPC1TDP1RAB9AALDH1A1LMNA | |
| SCHEMBL29540761 | 0.73 | ALDH1A1 (0.42) | NPC1SLC5A2ALDH1A1LMNACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-05-11 | — | — | US | disclosed |
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CDK1, CSNK1A1, CSNK1G1 | NPC1 1709/4885F2RL1 3648/4885DGAT1 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.